| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2007;38:204.)
© 2007 American Heart Association, Inc.
Cochrane Corner |
From the Division of Clinical Neurosciences, Centre for Clinical Brain Sciences, School of Molecular and Clinical Medicine, University of Edinburgh, UK.
Correspondence to Dr Rustam Al-Shahi, MA PhD MRCP(UK), MRC clinician scientist, Bramwell Dott Building, Division of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK. E-mail Rustam.Al-Shahi@ed.ac.uk
Section Editor: Graeme J. Hankey MD, FRCP
Key Words: acute cerebral hemorrhage intracerebral hemorrhage emergency treatment of stroke other stroke treatment, medical
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
| Introduction |
|---|
| Objective |
|---|
| Search Strategy |
|---|
| Selection Criteria |
|---|
| Data Collection and Analysis |
|---|
| Main Results |
|---|
-aminocaproic acid and 371 received recombinant activated factor VII [rFVIIa]).
Hemostatic drugs reduced the relative risk of death within 90 days of nontraumatic ICH (risk reduction [RR] 0.67; 95% CI, 0.46 to 0.97, random effects; Figure). Specifically, rFVIIa appeared to reduce the risk of death or dependence on the modified Rankin Scale (grades 4 to 6) within 90 days of nontraumatic ICH (RR 0.79; 95% CI, 0.67
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |